Risk factors for candidemia with non-albicans Candida spp. in intensive care unit patients with end-stage renal disease on chronic hemodialysis

• Main Authors: Kivanc Serefhanoglu, Funda Timurkaynak, Fusun Can, Unal Cagir, Hande Arslan, F. Nurhan Ozdemir
• Format: Article
• Language: English
• Published: Elsevier 2012-06-01
• Series: Journal of the Formosan Medical Association
• Subjects: non-albicans candidemia; chronic renal failure
• Online Access: http://www.sciencedirect.com/science/article/pii/S0929664612000411

The objective of this study was to describe factors associated with bloodstream infections (BSIs) with non-albicans Candida species (NAC), compared with Candida albicans BSIs, and antifungal susceptibility patterns in adult intensive care unit (ICU) patients with chronic renal failure undergoing hemodialysis. To the best of our knowledge, this is the first study to report the potential factors for NAC candidemia in ICU patients with end-stage renal disease on chronic hemodialysis. Methods: This prospective, observational, multicenter study was conducted in the two centers of Baskent University between January 2007 and July 2010. All adult patients excluding patients with neutropenia, malignancy, glucocorticoid treatment or AIDS, were included. Results: Sixty cases (58.8%) of candidemia were due to C. albicans and 42 (41.2%) to NAC. Multivariate regression analysis revealed that the presence of a central venous catheter was the only risk factor independently associated with BSI due to NAC (p=0.046, odds ratio: 5.90, 95% confidence interval: 1.032–33.717). Mortality was more frequent in those with NAC than C. albicans BSIs (64.3% vs. 55%), but the difference was not significant (p=0.067). Except for two Candida glabrata strains, which were dose–dependently fluconazole susceptible, all Candida species were susceptible to fluconazole, caspofungin, voriconazole and amphotericin B. Conclusion: Central venous catheterization was the only factor significantly associated with BSI due to NAC in ICU patients with end-stage renal disease.